Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 5:00 PM ET

Company Participants

Megan Jones - Vice President of Investor Relations

Kevin Conroy - Chairman and Chief Executive Officer

Jeff Elliott - Chief Financial Officer

Everett Cunningham - Chief Commercial Officer

Conference Call Participants

Derik de Bruin - Bank of America

Catherine Schulte - Baird

Vijay Kumar - Evercore ISI

Dan Brennan - TD Cowen

Brandon Couillard - Jefferies

Patrick Donnelly - Citi

Dan Arias - Stifel

Jack Meehan - Nephron Research

Matt Sykes - Goldman Sachs

Andrew Brackmann - William Blair

Puneet Souda - Leerink Partners

Dan Leonard - Credit Suisse

Mark Massaro - BTIG

Andrew Cooper - Raymond James

Kyle Mikson - Canaccord Genuity

Liza Garcia - UBS

Alex Nowak - Craig-Hallum Capital

Operator

Good day and welcome to the Exact Sciences Second Quarter 2023 Earnings Call. Today's call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the conference over to Megan Jones, Vice President of Investor Relations. Please go-ahead.

Megan Jones

Thanks, Lisa. Thank you for joining us for Exact Sciences second quarter 2023 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, will also be available for questions.

Exact Sciences issued a news release earlier this afternoon detailing our second quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release. And descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website.

I'll now turn the call over to Kevin.

Kevin Conroy

Exact Sciences’ world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA and proteins. They are intensely focused on enhancing our current tests and developing new tests that can help transform cancer care. The scale of Exact Sciences labs, IT infrastructure, commercial teams and our depth of payer relationships will help those tests impact millions of patients while providing profitable growth for years to come.